Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butenafine is a synthetic benzylamine antifungal drug used topically to treat various fungal skin infections, including tinea versicolor (caused by Malassezia furfur), athlete’s foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris). It is structurally related to allylamine antifungals such as terbinafine and naftifine. The primary mechanism of action involves inhibition of the squalene epoxidase enzyme, which is essential for the synthesis of sterols required for fungal cell membrane integrity. This leads to altered cellular membranes in fungi, increased membrane permeability, growth inhibition, and ultimately fungicidal activity. Butenafine demonstrates superior activity against dermatophytes compared to several other topical antifungals and also shows efficacy against Candida albicans, Cryptococcus neoformans, and Aspergillus species[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butenafine.